CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) General Information
Description
Worldwide rights for novel EGFR dual-targeting CAR. Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD).
Contact Information
Corporate Office
- San Diego, CA
- United States
Corporate Office
- San Diego, CA
- United States
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) FAQs
-
Where is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) headquartered?
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) is headquartered in San Diego, CA.
-
What industry is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) in?
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)’s primary industry is Buildings and Property.
-
Is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) a private or public company?
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) is a Private company.
-
What is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)’s current revenue?
The current revenue for CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) is .
-
Who are CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)’s investors?
Cytoimmune Biologics has invested in CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR).
-
When was CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) acquired?
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) was acquired on 03-Aug-2020.
-
Who acquired CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)?
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) was acquired by Cytovia Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process